doi:10.19428/j.cnki.sjpm.2021.20991

引用本文: 林剑生, 沈佳莹, 曹广文. 新型冠状病毒疫苗的种类、机制及临床试验效果[J]. 上海预防医学, 2021, 33(11): 1088-1095. doi: 10.19428/j.cnki.sjpm.2021.20991 shu

Citation: LIN Jian-sheng, SHEN Jia-ying, CAO Guang-wen . Category and working mechanisms of SARS-CoV-2 vaccines and their effectiveness in clinical trials[J]. Shanghai Journal of Preventive Medicine, 2021, 33(11): 1088-1095. doi: 10.19428/j.cnki.sjpm.2021.20991 shu

新型冠状病毒疫苗的种类、机制及临床试验效果

林剑生 ^1, ,
沈佳莹 ^2, ,
曹广文 ^{3,
,}

作者简介: 林剑生，男，硕士在读；研究方向：公共卫生；E-mail：z549460739@163.com

通讯作者: 曹广文, gcao@smmu.edu.cn

1.
暨南大学基础医学院，广东广州 510632
2.
同济大学医学院，上海 200331
3.
海军军医大学流行病学教研室，上海 200433
基金项目: 国家自然科学基金（82041022）；上海科学技术委员会项目（20JC1410200；20431900404）

摘要 : 自新型冠状病毒肺炎（COVID⁃19）暴发以来，全球累计确诊病例已超过120 915 219例，确诊死亡2 674 078例，超过223个国家或地区的经济和卫生资源遭受到不同程度的影响。目前，临床上尚无针对COVID⁃19的特效药，公共卫生政策实施难度大，各种疫苗的研发进展就引起了极大的关注。本文介绍了目前针对COVID⁃19开发较为热门的灭活疫苗、减毒活疫苗、重组亚单位疫苗、重组病毒载体疫苗、脱氧核糖核酸（DNA）疫苗和核糖核酸（RNA）疫苗的研究进展、优势和不足，提倡多个平台的疫苗共同研发，有助于更好地控制和预防COVID⁃19。

关键词:

English

Category and working mechanisms of SARS-CoV-2 vaccines and their effectiveness in clinical trials

Corresponding author: CAO Guang-wen, gcao@smmu.edu.cn

1.
School of Medicine，Jinan University，Guangzhou，Guangdong 510632，China
2.
Tongji University School of Medicine，Shanghai 200331，China
3.
Department of Epidemiology，Naval Medical University，Shanghai 200433，China
Received Date: 2021-03-19
Available Online: 2021-11-20

Abstract: Since the pandemic outbreak of the COVID-19， there had been about 121 million confirmed cases and more than 2.6 million deaths， which had significantly affected the economies and health resources in more than 233 countries and regions. Currently， no effective therapeutic option is available for the COVID-19， andimplementation of public health interventions suffers inconvenience. Consequently， the development of COVID-19 vaccines remains crucial. This review updates the current research progression， advantages and disadvantages of inactivated vaccine， live attenuated vaccine， recombinant subunit vaccine， recombinant virus-vectored vaccine， DNA vaccine， and RNA vaccine for the COVID-19. It warrants joint research and development of vaccines on multiple platforms， which would facilitate better control and prevention of the COVID-19 epidemic.

Key words:

1. [1]
  World Health Organization. WHO coronavirus（COVID-19）dashboard［EB/OL］.（2021-03-18）［ 2021-03-18］. https：//covid19.who.int.
2. [2]
  YADDANAPUDI K, MENG S H, WHITT A G.Exosomes from GM-CSF expressing embryonic stem cells are an effective prophylactic vaccine for cancer prevention[J]. Oncoimmunology, 2019, 8, (3): 1561119-.
3. [3]
  LIAO, WANG, KO Y A.Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes[J]. Proc Natl Acad Sci USA, 2020, 117, (30): 17757-17763.
4. [4]
  BLACK S, BLOOM D E, KASLOW D C.Transforming vaccine development[J]. Semin Immunol, 2020, 50: 101413-.
5. [5]
  曹广文. 新型冠状病毒进化、相关流行特征和特异性防控中的关键问题［J］. 上海预防医学，2020，32（9）：697- 703.
6. [6]
  KETEMA D B, ASSEMIE M A, ALAMNEH A A.Full vaccination coverage among children aged 12~23 months in Ethiopia： a systematic review and meta-analysis[J]. BMC Public Health, 2020, 20, (1): 777-.
7. [7]
  SOLEIMANPOUR S, YAGHOUBI A.COVID-19 vaccine： where are we now and where should we go？[J]. Expert Rev Vaccines, 2021, 20, (1): 23-44.
8. [8]
  KRAMMER F.SARS-CoV-2 vaccines in development[J]. Nature, 2020, 586, (7830): 516-527.
9. [9]
  LIU M A.Immunologic basis of vaccine vectors[J]. Immunity, 2010, 33, (4): 504-515.
10. [10]
  ZHANG Y N, CHEN C, DENG C L.A novel rabies vaccine based on infectious propagating particles derived from hybrid VEEV-Rabies replicon[J]. EBioMedicine, 2020, 56: 102819-.
11. [11]
  SCHILLER J T, LOWY D R.Raising expectations for subunit vaccine[J]. J Infect Dis, 2015, 211, (9): 1373-1375.
12. [12]
  成传刚，慕婷，袁军，等. 重组病毒载体疫苗研究进展［J］. 中国病毒病杂志，2018，8（4）：318- 328.
13. [13]
  ZHANG S J, HUANG W X, ZHOU X Y.Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults[J]. J Med Virol, 2013, 85, (6): 1077-1084.
14. [14]
  WEKEN HVAN DER, COX E, DEVRIENDT B.Advances in oral subunit vaccine design[J]. Vaccines （Basel）, 2020, 9, (1): 1-.
15. [15]
  ARASHKIA A, JALILVAND S, MOHAJEL N.Severe acute respiratory syndrome-coronavirus-2 spike （S） protein based vaccine candidates： state of the art and future prospects[J]. Rev Med Virol, 2021, 31, (3): -.
16. [16]
  WANG Z, TROILO P J, WANG X.Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation[J]. Gene Ther, 2004, 11, (8): 711-721.
17. [17]
  KIM J, EYGERIS Y, GUPTA M.Self-assembled mRNA vaccines[J]. Adv Drug Deliv Rev, 2021, 170: 83-112.
18. [18]
  TOMBÁCZ I, WEISSMAN D, PARDI N.Vaccination with messenger RNA： a promising alternative to DNA vaccination[J]. Methods Mol Biol, 2021, 2197: 13-31.
19. [19]
  World Health Organization. COVID-19 vaccine tracker and landscape［EB/OL］.（2021-03-02）［ 2021-03-18］. https：//www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
20. [20]
  XIA S L, ZHANG Y T, WANG Y X.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine， BBIBP-CorV： a randomised， double-blind， placebo-controlled， phase 1/2 trial[J]. Lancet Infect Dis, 2021, 21, (1): 39-51.
21. [21]
  U.S. National Library of Medicine. Clinical trial to evaluate the efficacy，immunogenicity and safety of the inactivated SARS-CoV-2 vaccine（COVID-19）［EB/OL］.（2020-11-27）［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04560881.
22. [22]
  ZHANG Y J, ZENG G, PAN H X.Safety， tolerability， and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18~59 years： a randomised， double-blind， placebo-controlled， phase 1/2 clinical trial[J]. Lancet Infect Dis, 2021, 21, (2): 181-192.
23. [23]
  WU Z W, HU Y L, XU M.Safety， tolerability， and immunogenicity of an inactivated SARS-CoV-2 vaccine （CoronaVac） in healthy adults aged 60 years and older： a randomised， double-blind， placebo-controlled， phase 1/2 clinical trial[J]. Lancet Infect Dis, 2021, 21, (6): 803-812.
24. [24]
  U.S. National Library of Medicine. Clinical trial for SARS-CoV-2 vaccine（COVID-19）［EB/OL］.（2020-10-09）.［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04582344.
25. [25]
  WANG H, ZHANG Y T, HUANG B Y.Development of an inactivated vaccine candidate， BBIBP-CorV， with potent protection against SARS-CoV-2[J]. Cell, 2020, 182, (3): 713-721.
26. [26]
  ELLA R, VADREVU K M, JOGDAND H.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine， BBV152： a double-blind， randomised， phase 1 trial[J]. Lancet Infect Dis, 2021, 21, (5): 637-646.
27. [27]
  SU F, PATEL G B, HU S H.Induction of mucosal immunity through systemic immunization： phantom or reality？[J]. Hum Vaccin Immunother, 2016, 12, (4): 1070-1079.
28. [28]
  MANGTANI P, ABUBAKAR I, ARITI C.Protection by BCG vaccine against tuberculosis： a systematic review of randomized controlled trials[J]. Clin Infect Dis, 2014, 58, (4): 470-480.
29. [29]
  v-vi .Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis[J]. Health Technol Assess, 2013, 17, (37): 1-372.
30. [30]
  O’NEILL L A J, NETEA M G.BCG-induced trained immunity： can it offer protection against COVID-19？[J]. Nat Rev Immunol, 2020, 20, (6): 335-337.
31. [31]
  SHARMA A, SHARMA S K, SHI Y F.BCG vaccination policy and preventive chloroquine usage： do they have an impact on COVID-19 pandemic？[J]. Cell Death Dis, 2020, 11, (7): 516-.
32. [32]
  ESCOBAR L E, MOLINA-CRUZ A, BARILLAS-MURY C.BCG vaccine protection from severe coronavirus disease 2019 （COVID-19）[J]. Proc Natl Acad Sci USA, 2020, 117, (30): 17720-17726.
33. [33]
  CHIMOYI L, VELEN K, CHURCHYARD G J.An ecological study to evaluate the association of Bacillus Calmette-Guerin （BCG） vaccination on cases of SARS-CoV2 infection and mortality from COVID-19[J]. PLoS One, 2020, 15, (12): -.
34. [34]
  LIU S J, YUAN C H, LIN J F.Association between vaccinations and clinical manifestations in children with COVID-19[J]. Transl Pediatr, 2021, 10, (1): 17-25.
35. [35]
  U.S. National Library of Medicine. A phase Ⅲ clinical trial to determine the safety and efficacy of ZF2001 for prevention of COVID-19［EB/OL］.（2020-11-30）［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04646590.
36. [36]
  DAI L P, ZHENG T Y, XU K.A universal design of betacoronavirus vaccines against COVID-19， MERS， and SARS[J]. Cell, 2020, 182, (3): 722-733.
37. [37]
  YANG S L, LI Y, DAI L P.Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults： pooled analysis of two randomized， double-blind， placebo-controlled， phase 1 and 2 trials[J]. medRxiv, 2020, : -. doi: 10.1101/2020.12.20.20248602
38. [38]
  U.S. National Library of Medicine. A study to evaluate the efficacy，responseimmune，and safety of a COVID-19 vaccine in adults ≥18 years with a pediatric expansion in adolescents（12 to< 18 years）at risk for SARS-CoV-2［EB/OL］.（2020-11-02）.［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04611802.
39. [39]
  U.S. National Library of Medicine. A controlled phase 2/ 3 study of adjuvanted recombinant SARS-CoV-2 trimeric S-protein vaccine（SCB-2019）for the prevention of COVID-19（SCB- 2019）［EB/OL］.（2021-02-09）.［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04672395.
40. [40]
  KEECH C, ALBERT G, CHO I.Phase 1~2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine[J]. N Engl J Med, 2020, 383, (24): 2320-2332.
41. [41]
  RICHMOND P, HATCHUEL L, DONG M.Safety and immunogenicity of S-Trimer （SCB-2019）， a protein subunit vaccine candidate for COVID-19 in healthy adults： a phase 1， randomised， double-blind， placebo-controlled trial[J]. Lancet, 2021, 397, (10275): 682-694.
42. [42]
  ZHU F C, LI Y H, GUAN X H.Safety， tolerability， and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine： a dose-escalation， open-label， non-randomised， first-in-human trial[J]. Lancet, 2020, 395, (10240): 1845-1854.
43. [43]
  U.S. National Library of Medicine. Phase Ⅲ trial of A COVID-19 vaccine of adenovirus vector in adults 18 years old and above［EB/OL］.（2021-01-22）.［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04526990.
44. [44]
  RAMASAMY M N, MINASSIAN A M, EWER K J.Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults （COV002）： a single-blind， randomised， controlled， phase 2/3 trial[J]. Lancet, 2021, 396, (10267): 1979-1993.
45. [45]
  ZHU F C, GUAN X H, LI Y H.Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older： a randomised， double-blind， placebo-controlled， phase 2 trial[J]. Lancet, 2020, 396, (10249): 479-488.
46. [46]
  FOLEGATTI P M, EWER K J, ALEY P K.Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2： a preliminary report of a phase 1/2， single-blind， randomised controlled trial[J]. Lancet, 2020, 396, (10249): 467-478.
47. [47]
  SADOFF J, LE GARS M, SHUKAREV G.Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine[J]. N Engl J Med, 2021, 384, (19): 1824-1835.
48. [48]
  LOGUNOV D Y, DOLZHIKOVA I V, SHCHEBLYAKOV D V.Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine： an interim analysis of a randomised controlled phase 3 trial in Russia[J]. Lancet, 2021, 397, (10275): 671-681.
49. [49]
  U.S. National Library of Medicine. A study to assess safety，tolerability，and ofVimmunogenicity591（COVID-19 vaccine）in healthy participants（V591- 001）［EB/OL］.（2021-03-11）［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04498247.
50. [50]
  U.S. National Library of Medicine. Safety and immunogenicity of the candidate vaccine MVA-SARS-2-S and a booster vaccination with a licensed vaccine against COVID-19［EB/OL］.（2020-09-29）［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04569383.
51. [51]
  U.S. National Library of Medicine. Phase Ⅰ~Ⅱ trial of dendritic cell vaccine to prevent COVID-19 in adults［EB/OL］.（2020-05-13）［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04386252.
52. [52]
  U.S. National Library of Medicine. Immunity and safety of Covid-19 synthetic minigene vaccine［EB/OL］.（2020-03-19）［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04276896.
53. [53]
  TEBAS P, YANG S P, BOYER J D.Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2： a preliminary report of an open-label， Phase 1 clinical trial[J]. EClinicalMedicine, 2021, 31: 100689-.
54. [54]
  U.S. National Library of Medicine. Safety，immunogenicity，and efficacy of INO-4800 for COVID-19 in healthy seronegative adults at high risk of SARS-CoV-2 exposure［EB/OL］.（2020-11-24）［ 2021-03-18］. https：//ClinicalTrials.gov/show/NCT04642638.
55. [55]
  WALSH E E, FRENCK R W JR, FALSEY A R.Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates[J]. N Engl J Med, 2020, 383, (25): 2439-2450.
56. [56]
  MULLIGAN M J, LYKE K E, KITCHIN N.Phase Ⅰ/Ⅱ study of COVID-19 RNA vaccine BNT162b1 in adults[J]. Nature, 2020, 586, (7830): 589-593.
57. [57]
  POLACK F P, THOMAS S J, KITCHIN N.Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine[J]. N Engl J Med, 2020, 383, (27): 2603-2615.
58. [58]
  BADEN L R, SAHLY H MEL, ESSINK B.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine[J]. N Engl J Med, 2021, 384, (5): 403-416.
59. [59]
  DOLGIN E.COVID-19 vaccines poised for launch， but impact on pandemic unclear[J]. Nat Biotechnol, 2020, : -. doi: 10.1038/d41587-020-00022-y
60. [60]
  CANDIDO D S, CLARO I M, DE JESUS J G.Evolution and epidemic spread of SARS-CoV-2 in Brazil[J]. Science, 2020, 369, (6508): 1255-1260.
61. [61]
  MUNNINK B B O, SIKKEMA R S, NIEUWENHUIJSE D F.Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans[J]. Science, 2021, 371, (6525): 172-177.
62. [62]
  LIU Y, LIU J Y, XIA H J.Neutralizing activity of BNT162b2-elicited serum-preliminary report[J]. N Engl J Med, 2021, 384: 1466-1468.
63. [63]
  SAHIN U, MUIK A, DERHOVANESSIAN E.COVID-19 vaccine BNT162b1 elicits human antibody and T_H1 T cell responses[J]. Nature, 2020, 586, (7830): 594-599.
64. [64]
  YANG P H, DING Y B, XU Z.Increased circulating level of interleukin-6 and CD8⁺ T cell exhaustion are associated with progression of COVID-19[J]. Infect Dis Poverty, 2020, 9, (1): 161-.
65. [65]
  JACKSON L A, ANDERSON E J, ROUPHAEL N G.An mRNA vaccine against SARS-CoV-2 preliminary report[J]. N Engl J Med, 2020, 383, (20): 1920-1931.
66. [66]
  徐芳，刘爽，严非，等. 国际疫苗监测系统管理经验借鉴［J］. 上海预防医学，2021，33（1）：73- 78.
1. [1]
  王霖 , 杜映荣 , 马志强 , 李杰 , 张淑琼 , 汤晓青 , 瞿春燕 , 段亚茹 , 李才信 . 新型冠状病毒疫苗接种6个月后血清IgM和IgG抗体水平的分析. 上海预防医学, 2022, 34(2): 126-129. doi: 10.19428/j.cnki.sjpm.2022.21598
2. [2]
  崔军 , 张涛 , 李辉 , 史碧君 . 社区慢性阻塞性肺疾病患者流感和肺炎疫苗接种意愿及影响因素. 上海预防医学, 2015, 27(7): 411-413.
3. [3]
  刘赛朵 , 蒋贤高 , 宁洪叶 , 叶新春 , 潘宁 , 吴正兴 , 周月影 , 邱超超 , 施伎蝉 . 42例新型冠状病毒肺炎的临床特征分析. 上海预防医学, 2020, 32(9): 736-739. doi: 10.19428/j.cnki.sjpm.2020.20092
4. [4]
  朱竹先 , 张晓林 , 李旭 , 张子强 . 高龄新型冠状病毒肺炎患者肝肾及凝血功能损伤的临床特征分析. 上海预防医学, 2020, 32(9): 732-735,745. doi: 10.19428/j.cnki.sjpm.2020.20345
5. [5]
  李环 , 徐健峰 , 孙晓丽 , 姚启哲 , 郭微 , 齐红霞 , 孙畅 . 辽宁省盘锦市12例新型冠状病毒肺炎的临床转归分析. 上海预防医学, 2020, 32(11): 918-921. doi: 10.19428/j.cnki.sjpm.2020.20355
6. [6]
  刘捷宸 , 陈勇 , 孙晓冬 , 沈妍琼 , 刘念 , 朱芳军 . 电子签名技术在疫苗冷链温度监测管理中的应用. 上海预防医学, 2020, 32(8): 614-617. doi: 10.19428/j.cnki.sjpm.2020.19871
7. [7]
  邓子如 , 严非 , 王伟 , 阿克忠 , 付朝伟 . 国际组织关于疫苗冷链配送的管理与实践及启示. 上海预防医学, 2021, 33(2): 141-145, 162. doi: 10.19428/j.cnki.sjpm.2021.20146
8. [8]
  臧召燕 , 王伟 , 严非 , 阿克忠 , 付朝伟 . 中国和亚洲部分其他国家疫苗配送管理的比较分析. 上海预防医学, 2021, 33(3): 243-247,253. doi: 10.19428/j.cnki.sjpm.2021.20145
9. [9]
  李保军 , 平建明 , 林鸿波 , 孙烨祥 . 手足口病疫苗接种年龄区间的流行病学探讨. 上海预防医学, 2014, 26(1): 10-13.
10. [10]
  刘敏勇 , 黄卓英 , 陆箐 , 杨建萍 , 杨玉颖 . 2015-2016年上海市脊髓灰质炎疫苗免疫策略调整前后婴儿抗体水平变化. 上海预防医学, 2020, 32(8): 627-630. doi: 10.19428/j.cnki.sjpm.2020.18789
11. [11]
  徐芳 , 刘爽 , 严非 , 王伟 , 阿克忠 , 付朝伟 . 国际疫苗监测系统管理经验借鉴. 上海预防医学, 2021, 33(1): 73-78. doi: 10.19428/j.cnki.sjpm.2021.20144
12. [12]
  孙晓冬 . 规范预防接种工作, 加强疫苗安全性评价. 上海预防医学, 2019, 31(4): 249-250. doi: 10.19428/j.cnki.sjpm.2019.19429
13. [13]
  朱珠英 , 郑琼琼 . 温州市龙湾区扩大国家免疫规划疫苗接种率调查. 上海预防医学, 2019, 31(7): 568-573. doi: 10.19428/j.cnki.sjpm.2019.18678
14. [14]
  陈一凡 , 曹广文 . 全国新型冠状病毒肺炎发病趋势初步分析. 上海预防医学, 2020, 32(2): 147-150. doi: 10.19428/j.cnki.sjpm.2020.20053
15. [15]
  王英鉴 , 张娜 , 吕涵路 , 周艺彪 . 上海市新型冠状病毒肺炎发病趋势初步分析. 上海预防医学, 2020, 32(2): 142-146. doi: 10.19428/j.cnki.sjpm.2020.20041
16. [16]
  韩明慧 , 方虹霁 , 杨东见 , 姜晨彦 , 陈传炜 , 王和兴 . 国外新型冠状病毒肺炎发病的现状和趋势分析. 上海预防医学, 2020, 32(3): 211-215. doi: 10.19428/j.cnki.sjpm.2020.20063
17. [17]
  王继伟 , 谷本哲也 , 赵天辰 , 津田健司 , 山下Erika , 上昌广 , 姜庆五 . 日本新型冠状病毒肺炎传播初期阶段的流行现状及应对. 上海预防医学, 2020, 32(4): 314-319. doi: 10.19428/j.cnki.sjpm.2020.20107
18. [18]
  谭晓㛃 , 钱治军 , 张宏伟 . 全国新型冠状病毒肺炎疫情初期治愈和死亡情况分析. 上海预防医学, 2020, 32(4): 309-313. doi: 10.19428/j.cnki.sjpm.2020.20081
19. [19]
  李文豪 , 熊鹏 , 赵心海 , 陈衍芳 , 刘博 , 刘敏 , 陈青山 . 中国应对新型冠状病毒肺炎本土疫情的策略和经验. 上海预防医学, 2020, 32(9): 704-711. doi: 10.19428/j.cnki.sjpm.2020.20326
20. [20]
  甄玲燕 , 应圣洁 , 吴蕴华 , 赵琬 , 朱效宁 , 丁克颖 . 新型冠状病毒肺炎防控留观酒店空调卫生状况调查. 上海预防医学, 2021, 33(6): 496-499. doi: 10.19428/j.cnki.sjpm.2021.20436

点击查看大图

计量

PDF下载量: 65
文章访问数: 1408
引证文献数: 0

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142